Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial

BACKGROUND: BK-SE36/CpG is a recombinant blood-stage malaria vaccine candidate based on the N-terminal Plasmodium falciparum serine repeat antigen5 (SE36), adsorbed to aluminium hydroxide gel and reconstituted, prior to administration, with synthetic oligodeoxynucleotides bearing CpG motifs. In heal...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouédraogo, Alphonse, Bougouma, Edith Christiane, Palacpac, Nirianne Marie Q., Houard, Sophie, Nebie, Issa, Sawadogo, Jean, Berges, Gloria D., Soulama, Issiaka, Diarra, Amidou, Hien, Denise, Ouedraogo, Amidou Z., Konaté, Amadou T., Kouanda, Seni, Myoui, Akira, Ezoe, Sachiko, Ishii, Ken J., Sato, Takanobu, D’Alessio, Flavia, Leroy, Odile, Tiono, Alfred B., Cousens, Simon, Horii, Toshihiro, Sirima, Sodiomon B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613650/
https://www.ncbi.nlm.nih.gov/pubmed/37908361
http://dx.doi.org/10.3389/fimmu.2023.1267372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613650/
https://www.ncbi.nlm.nih.gov/pubmed/37908361
http://dx.doi.org/10.3389/fimmu.2023.1267372

Ejemplares similares